A new study by Deloitte focusing on the “cannabis 2.0” stage of legalization in Canada projects that the upcoming edibles market will be worth over C$2.7 billion per year.

The report, published on Monday (June 3), is the research firm’s third annual study of the Canadian cannabis market.

Deloitte projects the heavily anticipated edibles and infused marijuana products market will offer C$2.7 billion annually, with edibles alone representing C$1.6 billion per year in Canada.

In a survey of consumers, gummies took the top spot for preferred edible items with a 26 percent market share, while cookies, brownies and chocolates rounded out list.

The research shows that another cannabis item that has caused a splash of interest will also offer some substantial value.

Cannabis-infused beverages represent C$529 million per year of the total edibles projection.

These drinks have gained notoriety among investors thanks to partnerships between cannabis firms and alcohol producers looking for an entry point into this market.

Some Canadian cannabis producers with beverage deals include: Canopy Growth (NYSE:CGC,TSX:WEED), Tilray (NASDAQ:TLRY) and HEXO (NYSEAMERICAN:HEXO,TSX:HEXO).

As the effects from adult-use legalization are still being seen across the country, industry players expect the opening of sales for edibles and infused items to be a shot in the arm to the overall space.

However, one Canadian firm recently expressed concerns about the expectations for beverages.

In a conference call with investors and analysts in May, Cam Battley, chief corporate officer with Aurora Cannabis (NYSE:ACB,TSX:ACB), said the firm has focused on products with strong demand using a model that is based on what the legal US state markets have experienced.

According to Battley, cannabis beverages secure a “low market share” in the total marketplace.

Jennifer Lee, partner at Deloitte and the firm’s cannabis leader for Canada, said cannabis-infused edibles will “clearly threaten” the established alcohol space in Canada.

“According to our research and stakeholder interviews, much of this economic boost will be on top of current cannabis product spending,” Lee said in a press release.

As part of its study, Deloitte interviewed a variety of industry players on the state of the market.

Edibles market offers Canadian players edge over US

As the Canadian market has seen the growing pains from its legalization path, the US space has seen exponential growth in investment and interest thanks to the emergence of multi-state operators, companies that manage assets in legal cannabis states.

Deloitte is bullish on the potential for the Canadian market to gain a spark from the entry of edibles and beverages.

The study indicates that the market will need to be patient as the regulations for edibles come into place.

“There will be missteps, delays, and frustration,” Deloitte says about the legal framework for cannabis and derivatives in Canada.

As mentioned, Deloitte refers to this new stage of legalization as “cannabis 2.0,” noting that, while it will take some time for the market to really establish itself, in time the momentum will be great enough to match the interest for the US market.

“Cannabis 2.0 will position Canadian companies and talent for global growth — even as the US market gains momentum,” the report states.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less